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Mutations in KARS, Encoding Lysyl-tRNA
Synthetase, Cause Autosomal-Recessive
Nonsyndromic Hearing Impairment DFNB89
Regie Lyn P. Santos-Cortez,1,8 Kwanghyuk Lee,1,8 Zahid Azeem,2,3 Patrick J. Antonellis,4,5
Lana M. Pollock,4,6 Saadullah Khan,2 Irfanullah,2 Paula B. Andrade-Elizondo,1
Ilene Chiu,1 Mark D. Adams,6 Sulman Basit,2 Joshua D. Smith,7 University of Washington
Center for Mendelian Genomics, Deborah A. Nickerson,7 Brian M. McDermott, Jr.,4,5,6
Wasim Ahmad,2 and Suzanne M. Leal1,*
Previously, DFNB89, a locus associated with autosomal-recessive nonsyndromic hearing impairment (ARNSHI), was mapped to chromo-
somal region 16q21–q23.2 in three unrelated, consanguineous Pakistani families. Through whole-exome sequencing of a hearing-
impaired individual from each family, missense mutations were identified at highly conserved residues of lysyl-tRNA synthetase
(KARS): the c.1129G>A (p.Asp377Asn) variant was found in one family, and the c.517T>C (p.Tyr173His) variant was found in the other
two families. Both variants were predicted to be damaging by multiple bioinformatics tools. The two variants both segregated with the
nonsyndromic-hearing-impairment phenotype within the three families, and neither mutation was identified in ethnically matched
controls or within variant databases. Individuals homozygous for KARS mutations had symmetric, severe hearing impairment across
all frequencies but did not show evidence of auditory or limb neuropathy. It has been demonstrated that KARS is expressed in hair cells
of zebrafish, chickens, andmice.Moreover, KARS has strong localization to the spiral ligament region of the cochlea, as well as to Deiters’
cells, the sulcus epithelium, the basilar membrane, and the surface of the spiral limbus. It is hypothesized that KARS variants affect ami-
noacylation in inner-ear cells by interfering with binding activity to tRNA or p38 and with tetramer formation. The identification of rare
KARS variants in ARNSHI-affected families defines a gene that is associated with ARNSHI.Hearing impairment (HI) affects nearly 300 million people
of all ages globally and increases in prevalence per decade
of life.1 Children and adults with bilateral, moderate-to-
profound HI have a poorer quality of life, which encom-
passes not only problems in physical function but also
socioemotional, mental, and cognitive difficulties.2,3 In
particular, children with congenital HI must be identified
and habilitated within the first 6 months of life so that de-
lays in the acquisition of speech, language, and reading
skills can be prevented.4
Among children with congenital sensorineural HI, more
than 80% do not display syndromic features and ~60%
have a family history of HI or a confirmed genetic etiol-
ogy.5 Because of the complex cellular organization of the
inner ear, hundreds of genes and proteins are predicted
to influence auditory mechanisms. To date, for nonsyn-
dromic HI (NSHI), about 170 loci have been localized
and mutations in ~75 genes have been identified in hu-
mans (Hereditary Hearing Loss Homepage). Of the gene
variants that have been implicated in NSHI, almost 60%
are autosomal recessive (AR) in inheritance, and 95% of
the genes that harbor mutations that cause ARNSHI were
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expression, and localization studies after the identification
of genes with mutations that cause NSHI has immensely
expanded our understanding of inner-ear physiology.
Previously, an ARNSHI-associated locus, DFNB89, was
mapped to chromosomal region 16q21–q23.2 in two unre-
lated, consanguineous Pakistani families.6 The two fam-
ilies, 4338 and 4406 (Figures 1A and 1B), had maximum
multipoint LOD scores of 6.0 and 3.7, respectively. The ho-
mozygosity regions that overlap in the two families led to
the identification of a 16.1 Mb locus (chr16: 63.6–79.7 Mb)
that includes 180 genes. Additionally, a third consanguin-
eous Pakistani family, 4284 (Figure 1C), was identified, and
showed suggestive linkage to the DFNB89 region with a
maximum multipoint parametric LOD score of 1.93. For
family 4284, linkage analysis was performed for ~6,000
SNP markers that were genotyped across the genome
with the Illumina Linkage Panel IVb.
Consanguineous families 4284, 4338, and 4406 from
Pakistan are affected by ARNSHI, which was found to
segregate with unique haplotypes within the DFNB89 lo-
cus (Figures 1A–1C). From the medical history, no other
risk factors were identified as a possible cause of HI. Fors, Baylor College of Medicine, Houston, Texas 77030, USA; 2Department of
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all HI individuals, there were no reports of vertigo or other
neurologic complaints. Additionally, from physical exami-
nation, no other syndromic, vestibular, neurologic, or sys-
temic abnormalities were detected. One HI individual from
each family, namely V-6 from family 4338, IV-2 from fam-
ily 4406, and IV-2 from family 4284 (Figures 1A–1C), was
tested for air-conduction audiometry (Figure 1D). Bilateral,
symmetric severe-to-profound hearing impairment was
demonstrated in HI individuals from families 4284 and
4338, whereas individual IV-2 from family 4406 had sym-
metric moderate-to-severe hearing impairment across all
frequencies tested (Figure 1D).
Before the commencement of the study, approval was
obtained from the institutional review boards of Quaid-i-
Azam University and Baylor College of Medicine and the
affiliated hospitals. Informed consent was obtained from
all family members who participated in the study. DNA
samples of HI individuals V-7 from family 4338, IV-5
from family 4406, and IV-1 from family 4284 (Figures
1A–1C) were submitted for whole-exome sequencing at
the University of Washington Center for Mendelian Geno-
mics. For families 4338 and 4406, sequence capture was
performed in solution with the Roche NimbleGen SeqCap
EZ Human Exome Library v.2.0 (~36.6 Mb of target
sequence), whereas for family 4284, the NimbleGen Big
Exome 2011 Library (EZ Exome v.3.0 with ~64 Mb target
sequence) was used. Sequencing was performed with an Il-
lumina HiSeq, and average read depths were 1213 for sam-
ple V-7 (family 4338), 99 3 for sample IV-5 (family 4406),
and 53 3 for sample IV-1 (family 4284). Fastq files were
aligned to the human reference sequence (UCSC Genome
Browser hg19) with the Burrows-Wheeler Aligner7 for the
generation of demultiplexed BAM files. Realignment of in-
del regions, recalibration of base qualities, and variant
detection and calling were performed with various compo-
nents of the Genome Analysis Toolkit8 for the production
of VCF files. Variant sites that were of low quality andmore
likely to be false positives were flagged. Annotation was
performed with SeattleSeq 137.
For all variants that were homozygous for the minor
allele and that were identified within the DFNB89
interval through exome sequencing, potentially func-
tional variants, including nonsense, missense, splice-site,
and indel variants, were screened for quality and against
public variant databases dbSNP, 1000 Genomes, and
the National Heart, Lung, and Blood Institute (NHLBI)
Exome Sequencing Project Exome Variant Server. Within
the DFNB89 interval, five rare missense variants within
four genes, namely COG4 (MIM 606976), ZFHX3 (MIM
104155), KARS (MIM 601421), and CNTNAP4 (MIM
610518), were homozygous for the nonreference allele
and were not observed in variant databases (Table 1).
Of these five missense variants, only variants within
KARS were observed in all three families affected by
DFNB89-associated ARNSHI (Table 1). Additionally, for in-
dividual IV-1 from family 4284, only one homozygous
KARS missense variant, c.517T>C (p.Tyr173His) (isoformThe Am1 [RefSeq accession number NM_001130089.1]), was
found within the DFNB89 locus and not in variant data-
bases and also passed quality measures. This same variant
was also homozygous in individual IV-5 from family
4406. On the other hand, individual V-7 from family
4338 was homozygous for KARS variant c.1129G>A
(p.Asp377Asn).
For missense variants that were of good quality and not
observed in variant databases, five bioinformatics tools
were used to evaluate potential functionality: PolyPhen-
2,9 SIFT,10 MutationTaster,11 MutationAssessor,12 and the
likelihood ratio test (LRT).13 Only the two variants within
KARS—c.1129G>A (p.Asp377Asn) and c.517T>C
(p.Tyr173His)—were deemed damaging by all five bioin-
formatics tools used for prediction of functionality of
missense variants (Table 1).
To estimate the evolutionary conservation of the nucle-
otides and the amino acid residues at which the variants
occur, we derived GERP14 and phyloP15 (with the phy-
loP46wayall option) scores from the UCSC Genome
Browser. Nucleotides c.1129G and c.517T within KARS
are highly conserved according to both PhyloP and GERP
scores (Table 1). Protein sequences from nonhuman spe-
cies were derived from the UniProtKB database with blastp
and were aligned with ClustalW2.16 Multiple-sequence
alignment of human KARS with 165 nonhuman KARS
and similar proteins from primates to fungi provided
further strong evidence of evolutionary conservation at
the amino acid residues where the two variants occur
(Figure 1E and Figure S1, available online). The tyrosine
residue at position 173 is highly conserved except in three
insect species, whereas the aspartic acid residue at position
377 is identical in all aligned sequences (Figure S1).
We sequenced variants predicted to be damaging in all
family members and 325 ethnically matched control indi-
viduals to check for segregation with HI. We designed
primers by using Primer3 software17 to amplify exons 5
and 9 of KARS. PCR-amplified DNA products were purified
with ExoSAP-IT (Affymetrix-USB) and sequenced with the
BigDye Terminator v.3.1 Cycle Sequencing Kit and an
Applied Biosystems 3730 DNA Analyzer (Life Technolo-
gies). DNA sequences were analyzed with Sequencher soft-
ware v.4.9 (Gene Codes). DNA samples from all available
family members were sequenced for KARS variant
c.1129G>A (p.Asp377Asn) in family 4338 and c.517T>C
(p.Tyr173His) in both families 4284 and 4406 (Figures
1A–1C and 1F). In all three families, the KARS variants
segregated with HI status. Neither KARS variant was identi-
fied in 650 ethnically matched control chromosomes.
Previously, an individual with both recessive intermedi-
ate Charcot-Marie-Tooth disease B (MIM 613641) and
bilateral acoustic neuroma was described in the literature
to have compound-heterozygous mutations in KARS.18
Additional testing was performed for the evaluation of
both conditions within the families affected by DFNB89-
associated ARNSHI. For HI individuals IV-2 and IV-7
from family 4406 (Figure 1B), tests for tympanometry,erican Journal of Human Genetics 93, 132–140, July 11, 2013 133
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Figure 1. Pedigree Drawings, Clinical Data, and Mutation Information for Families Affected by KARS Variants
(A–C) Family 4338 (A), affected by the c.1129G>A (p.Asp377Asn) variant, and families 4406 (B) and 4284 (C), affected by the c.517T>C
(p.Tyr173His) variant segregating with hearing impairment. Each family has a unique haplotype within the DFNB89 locus.
(D) Air-conduction audiograms for individuals V-6 of family 4338 (black solid), IV-2 of family 4406 (gray), and IV-2 of family 4284 (black
dotted). Circles are for the right ear, and crosses are for the left ear. All three individuals have symmetric, moderate-to-profound impair-
ment across all frequencies.
(E) Multiple-sequence alignment showing evolutionary conservation of amino acid residues Asp377 and Tyr173 (black arrows) in hu-
mans, chickens, mice, and zebrafish.
(F) Chromatograms comparing an HI individual who is homozygous for each KARS variant, a heterozygous carrier, and an individual
with normal hearing.
(G) Auditory brainstem response (ABR) tracings at 80–100 dB from two individuals from family 4406. Red lines are for the right ear, and
blue lines are for the left ear. Crosses mark the latency peaks at waves I, III, and V. ABR waveforms were well formed in both individuals
but showed unilateral delay in interpeak latencies I-III or I-Vand a difference> 0.2ms in the interaural latencies of wave V. For individual
(legend continued on next page)
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Table 1. Bioinformatic Evaluation of Rare Missense Variants Observed from Exome Sequence Data to Be within the DFNB89 Region at
16q21–q23.2
Sample ID
4406 IV-5 4406 IV-5 4406 IV-5 and 4284 IV-1 4338 V-7 4338 V-7
hg19 coordinate 70,543,852 72,830,796 75,670,401 75,665,624 76,587,774
Gene COG4 ZFHX3 KARS KARS CNTNAP4
RefSeq accession number NM_015386.2 NM_006885.3 NM_001130089.1 NM_001130089.1 NM_033401.3
Nucleotide mutation c.811A>G c.5785C>T c.517T>C c.1129G>A c.3703G>A
PhyloPa 2.37 1.18 4.89 6.04 2.24
GERPb 5.61 2.48 5.96 6.03 3.47
Amino acid substitution p.Ile271Val p.Pro1929Ser p.Tyr173His p.Asp377Asn p.Ala1235Thr
PolyPhen-2c benign benign probably damaging probably damaging benign
SIFT tolerated tolerated damaging damaging tolerated
MutationTaster disease causing polymorphism disease causing disease causing disease causing
Mutation Assessor neutral neutral functional, high functional, high not available
LRT deleterious neutral deleterious deleterious deleterious
All variants listed are absent from publically available databases. The following abbreviation is used: LRT, likelihood ratio test.
aPhyloP scores indicate nucleotide conservation under a null hypothesis of neutral evolution.
bGERP provides position-specific estimates of evolutionary constraint.
cBased on HumVar data set for PolyPhen-2.otoacoustic emissions (OAEs), and auditory brainstem
response (ABR) were performed (Figure 1G). In both HI in-
dividuals, OAEs were absent and well-formed ABR wave-
forms were present (Figure 1G), thus ruling out auditory
neuropathy and supporting the occurrence of cochlear pa-
thology, particularly of the outer hair cells. Although the
ABR waveforms in both individuals showed unilateral
delay in interpeak latencies I-III or I-V and a difference >
0.2 ms in the interaural latencies of wave V (Figure 1G
and Table S1), the delay in interpeak I-III or I-V for individ-
ual IV-2 was seen only at 100 dB, but not at 90 dB. Addi-
tionally, individual IV-7 had an absent compliance peak
during tympanometry of the left ear, which is suggestive
of otitis media or middle-ear effusion at the time of testing.
To further exclude Charcot-Marie-Tooth disease (CMT), we
tested HI individual V-6 from family 4338 (Figure 1A) for
nerve conduction velocity of the median, tibial, common
peroneal, and sural nerves and for electromyography of
the abductor pollicis brevis, first dorsal interosseous,
extensor hallucis longus, and tibialis anterior muscles. All
motor and sensory action potentials were bilaterally
normal; thus, in this individual, CMT is unlikely.
To predict the possible effect of KARS variants on protein
structure, we used InterProScan19 to search for protein sig-
natures within KARS and used SWISS-MODEL20 for protein
modeling. The KARS c.517T>C (p.Tyr173His) variant was
identified in two families (4284 and 4406) affected byIV-2, the delay in interpeak I-III or I-V was seen only at 100 dB, but no
peak from tympanometry on the left ear, suggesting otitis media or m
latency delays on the left ear compared to the right ear. Otoacoustic e
out auditory neuropathy.
The AmDFNB89-associated ARNSHI. When modeled on the basis
of the known structure of human KARS (Protein Data
Bank ID 3BJU),21 position 173 occurs within b strand 2,
and the change from the aromatic side chain of tyrosine
to the basic side chain of histidine results in the loss of
an H-bond with the asparagine residue at position 201
within a-helix 3 (Figures S2A and S2B). MutationTaster pre-
dicted the p.Tyr173His variant to cause the loss of the b
strand. The residue at position 173 also forms two H-bonds
with valine at position 184 within b strand 3; however,
despite the amino acid change, these two bonds, which
contribute to the maintenance of the antiparallel sheet,
remain unchanged (Figures S2A and S2B).
The tyrosine residue at position 173 is predicted to occur
within the oligomer-binding (OB)-foldmotif of thenucleic-
acid- or anticodon-binding domain. The OB-fold motif is
composed of a highly conserved five-stranded b-barrel
that is further organized into a b-meander made up of b
strands 1–3 and a b-hairpin made up of b strands 4 and 5;
the b-meander and b-hairpin are connected by a less
conserved a-helix (i.e., a-helix 3 in KARS), which caps the
entire b-barrel.22 Of the b-barrel components in KARS,
strands b-1 and b-2 are least resistant to denaturation,23
which might imply the importance of the stability of these
strands to the domain structure. The tyrosine residue at po-
sition173 lies in themiddle of the b-2 strand, and the loss of
theH-bondwith an asparagine residue ata-helix 3probablyt at 90 dB. Additionally, individual IV-7 had an absent compliance
iddle-ear effusion at the time of testing, which could explain the
missions (OAEs) were bilaterally absent in both individuals, ruling
erican Journal of Human Genetics 93, 132–140, July 11, 2013 135
Figure 2. Expression of KARS in Chicken
Hair Cells
Expression of KARS in purified chicken
hair cells was detected by RNA-seq. The
alignment of reads was visualized with
the Integrative Genomics Viewer; blue
read color represents forward orientation
relative to the reference genome, and red
color represents reverse reads.affects the conformation of the b-barrel within the OB-fold
motif. Moreover, the tyrosine residue at position 173 is
adjacent to a phenylalanine residue that aligns with the
active binding site of the anticodon-binding domain of
aspartyl-tRNA synthetase (DARS).22 The p.Tyr173His
variant is therefore hypothesized to interfere with tRNA
binding and consequently the catalytic activity of KARS.
For family 4338, the KARS c.1129G>A (p.Asp377Asn)
variant was found to segregate with HI. For position 377
within a-helix 9 of KARS, when the acidic side chain of
the aspartic acid residue is changed to the amide side chain
of asparagine, the H-bonds with glutamic acid at position
380 and isoleucine at 381 are maintained (Figures S2C
and S2D). On the other hand, one out of three H-bonds
with the aspartic acid residue at position 374, particularly
the bond between the amine group at 374 and the
carboxyl side chain at 377, is lost (Figures S2C and S2D).
Also, the amino acid change introduces an H-bond with
the lysine residue at position 126 of another KARS mono-
mer within the tetrameric structure (Figures S2C and
S2D). The amide side chain of asparagine has a different
rotation angle than does the carboxyl side chain of aspartic
acid. MutationTaster predicted the p.Asp377Asn variant
to cause the loss of the a-helical structure. It can be seen
that the H-bond-formation changes due to p.Asp377Asn
interfere with the formation of the a-helix and cause the
subsequent loss of the H-bond between the C¼O group
of tyrosine at position 375 and the NH group of leucine
at 378 (Figures S2C and S2D).
In addition to having a role in charging lysyl-tRNA mol-
ecules, KARS plays a role in the stabilization of the multi-
synthetase complex (MSC) because of the high affinity of
MSC scaffold proteins (e.g., p38) to KARS.24 The aspartic
acid residue at position 377 within a-helix 9 of the amino-
acylation domain is three residues upstream of the KARS
tetramer interface that not only creates binding surfaces
for KARS dimers to interact but also binds p38 scaffolding
protein within the MSC.21 Loss of a-helix 9 due to the
c.1129G>A (p.Asp377Asn) variant that was identified in
family 4338 is predicted to affect the configuration of the136 The American Journal of Human Genetics 93, 132–140, July 11, 2013tetramer interface. Additionally, the
fact that the p.Asp377Asn variant
causes the gain of an H-bond with
another KARS monomer might affect
dimer or tetramer formation. KARS is
least active in aminoacylation as a
tetramer that is unbound to p38, whereas the p38-bound
KARS dimer and tetramer are both more than twice as
active as the unbound tetramer.25 The p.Asp377Asn
variant might also affect KARS activity by changing the
equilibrium of the bound and unbound dimer-tetramer
forms of KARS.
To further elucidate the role of KARS in hearing, we
tested the occurrence of KARS cDNA in hair cells in
chickens, zebrafish, and mice. All animals were kept with
the approval of the Case Western Reserve University Insti-
tutional Animal Care and Use Committee. Sensory patches
were dissected from white leghorn chickens that were less
than 3 weeks old and incubated for 20 min in dissociation
chicken saline solution (154mMNaCl, 6 mM KCl, 0.1 mM
CaCl2, 8 mM glucose, and 5 mM HEPES [pH ¼ 7.4]) with
Type XXVI endopeptidase (Sigma-Aldrich) at 0.1 mg/ml.
After trituration, 200 hair cells were isolated by picking
with a glass micropipette.26 RNA was isolated from these
cells, and this was followed by synthesis and amplification
of cDNA (Ovation RNA-Seq System, NuGen Technologies),
which was subjected to massively parallel sequencing with
an Illumina HiScan for the production of single-end reads.
Quality control was performed on the raw sequencing data
with FASTQC software, and TopHat27 was used for aligning
the reads to the galGal3 reference genome. Cufflinks28 was
then used on these alignment files for the generation of a
transcriptome assembly. There were 103,045,330 total
mapped reads. Expression values for each transcript were
calculated as read counts (1,012 reads aligned to KARS
and 1,286 reads aligned to protocadherin 15 or PCDH15),
and the read alignments to galGal4 were viewed with the
Integrated Genome Viewer29 through the Galaxy plat-
form.30–32 KARS is expressed in chicken hair cells (Figure 2),
as determined by massively parallel sequencing of the hair
cell transcriptome. The reads per kilobase per million map-
ped reads was 4.61 for KARS (RefSeq NM_001030583) and
1.84 for PCDH15 (RefSeq NM_001044654), a gene which is
known to be expressed specifically in hair cells.33
For RT-PCR experiments, zebrafish cDNA was produced
from purified adult hair cells, adult maculae, and whole
* * *
C D
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_
Figure 3. Expression and Localization of Kars in Zebrafish and
Mice
RT-PCR analyses of zebrafish (A) and mouse (B) Kars mRNAs with
the use of three separate primer sets for each species (Table S2).
Tick marks in (A) and (B) correspond to molecular weights of
500 bp (upper) and 400 bp (lower). Confocal images of whole-
mount mouse vestibular tissue (C and D) and cochlear cryosec-
tions (E–H) are displayed. Scale bars represent 1 mm in (A) and
(B) and 10 mm in (C)–(H).
(A) Agarose gel confirms the expected amplicon size with the use
of primer set 1, directed toward kars cDNA with zebrafish hair
cell (HC), macula (M), and whole fish (WF) cDNA templates
(lanes 1, 2, and 3, respectively). No product was observed
without the template (–) (lane 4). The same pattern of template
cDNAs was repeated for primer sets 2 (lanes 5–8) and 3 (lanes
9–12).
(B) Agarose gel confirms the expected Kars amplicon size with the
use of primer set 1 and mouse macula cDNA (lane 1), but no prod-
uct was observed without the template (lane 2). The same pattern
of template cDNA was used for primer sets 2 (lanes 3–4) and 3
(lanes 5–6).
(C) Mouse vestibular tissue labeled with KARS polyclonal antibody
(green) and phalloidin (red) reveals the broad distribution of KARS
in hair cells and supporting cells.
(D) Control mouse vestibular tissue labeled with only secondary
antibody and phalloidin.
(E) Mouse organ of Corti section labeled with KARS antibody and
phalloidin demonstrates KARS localization to inner hair cells,
outer hair cells, and supporting cells. Hair cell nuclei are denoted
by asterisks.
(F) Control organ of Corti tissue labeled exclusively with second-
ary antibody.
The Amembryos. Adult hair cell and macula cDNA were produced
as previously described.26 To make cDNA from the whole
fish, we isolated RNA from approximately 20 embryos
that were 7 days postfertilization (RNeasy Mini Kit,
QIAGEN) and used it to synthesize randomly primed
cDNA (SuperScript III Reverse Transcriptase, Life Technolo-
gies). We followed the same procedure to produce cDNA
from maculae of three adult mice of the FVB/NJ strain.
PCR amplifications were performed (Ex Taq DNA Polymer-
ase, Takara Bio) with interexonic primers designed to
recognize different exons of Kars of either the zebrafish
or the mouse. Each primer set (Table S2) was used with
PCR parameters designed to amplify a segment of the
Kars cDNA, but not the genomic locus. Kars expression
was detected in zebrafish hair cells and in maculae of
both zebrafish and mice (Figures 3A and 3B).
For immunolabeling experiments, 6- to 12-month-old
FVB/NJ mice were used. The vestibular tissue was extracted
and fixed in 4% paraformaldehyde (PFA) in PBS for 1 hr. Af-
ter three washes with PBS, the tissue was permeabilized
with 0.05% Triton X-100 in PBS for 2 hr and then blocked
with 1% BSA in 0.05% Triton X-100 for 2 hr. The tissue was
then incubated overnight at 4C with primary antibody
(rabbit polyclonal to Lysyl tRNA synthetase ab31532, Ab-
cam) at a 1:300 dilution in blocking solution. This anti-
body has been effectively used for immunolabeling fixed
cultured cells.34 After a 30 min wash in PBS, the tissue
was incubated with secondary antibody (Alexa Fluor 488
goat anti-rabbit IgG, Life Technologies) at a 1:200 dilution,
and actin filaments were labeled with phalloidin (Alexa
Fluor 568 phalloidin, Life Technologies) at a 1:50 dilution.
After a final 30 min wash in PBS, the tissue was mounted
on a slide with mounting medium (Vectashield, Vector
Laboratories). For immunolabeling of the cochlea, the in-
ternal ears of mice were removed, fixed, and sectioned as
previously described.26 Sections were postfixed with 4%
PFA for 15 min and then washed three times with PBS.
We performed antigen retrieval by incubating sections
for 5 min with 1% sodium dodecyl sulfate and washing
them three times with PBS. Sections were blocked with
5% goat serum and 0.1% Triton X-100 in PBS for 1 hr. Spec-
imens were sequentially incubated with primary and sec-
ondary antibodies diluted in 5% goat serum and 0.1%
Triton X-100. Prior to imaging, sections were set in Vecta-
shield with a coverslip. All immunolabeled images were
captured with a laser-scanning confocal microscope (Leica
Microsystems) and a 403 oil-immersion objective.
Hair cells of the vestibular system exhibited labeling
with KARS antibody (Figures 3C and 3D). Additionally,
within the mouse organ of Corti, KARS was localized to
the inner and outer hair cells, Deiters’ cells, and the basilar
membrane (Figure 3E). The tectorial membrane showed a(G) A cochlear section reveals KARS localization to an area that
contains otic fibrocytes (arrowhead). Localization to this area
was observed in 41% (n ¼ 21) of sections.
(H) Control, cochlear section labeled with only secondary anti-
body and phalloidin.
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strong affinity for KARS antibody, and KARS labeling was
strongest within the spiral ligament, particularly in
the area containing type II and Type IV fibrocytes
(Figure 3G). KARS was also strongly localized to the outer
and inner sulcus cells and spiral limbus epithelium. On
the other hand, KARS showed weak localization to the stria
vascularis, Reissner’s membrane, and cochlear nerve end-
ings (Figure 3G).
In this report, three ARNSHI-affected families that segre-
gate different haplotypes overlapping within the DFNB89
interval6 were found to each have a missense mutation
within KARS, which encodes a ubiquitously expressed pro-
tein, lysyl-tRNA synthetase (UniGene 131351 – Hs.3100).
Many genes that are involved in the etiology of ARNSHI
also encode ubiquitously expressed proteins, e.g., ESRRB
(DFNB35),35 HGF (DFNB39),36 ILDR1 (DFNB42),37 and
MSRB3 (DFNB74)38 to name a few.
Fourteen human phenotypes, all of which manifest as
neurologic defects, are due to mutations in amino-acyl
tRNA synthetase (ARS)-encoding genes, nine of which
are mitochondrial. Of these phenotypes, five include
sensorineural hearing impairment, namely Perrault syn-
drome (from mutations in mitochondrial leucyl-tRNA
synthetase 2 [LARS2 [MIM 604544]39 and histidyl-tRNA
synthetase 2 [HARS2 [MIM 600783]),40 Usher syndrome
type IIIB (MIM 614504) (caused by a homozygous variant
in cytoplasmic histidyl-tRNA synthetase [HARS (MIM
142810)]),41 CMT type 2N (MIM 613287) (due to a variant
in dominant alanyl-tRNA synthetase [AARS (MIM
601065)]),42 and pontocerebellar hypoplasia type 6
(caused by compound-heterozygous mutations in
arginyl-tRNA synthetase 2 [RARS2 (MIM 611524)]).43
Functional studies for the missense mutations in these
ARS-encoding genes showed adequate localization but
decreased aminoacylation activity.40–42 Alternatively, ARS
variants that have normal enzymatic and localizing capa-
bilities can also have decreased aminoacylation activity
as a result of misfolding and failure to adopt a globule-
like state.44
For KARS, studies using bacteria and cultured mamma-
lian cell lines have demonstrated that KARS mutations
result in a temperature-regulated decrease in KARS activity
or cell apoptosis.45,46 An individual with CMT was found
to have compound-heterozygous KARS variants18
c.398T>A (p.Leu133His) and a duplication of TT nucleo-
tides, which results in a frameshift change and leads to a
null allele via nonsense-mediated decay. It was previously
shown that these two KARS variants significantly reduce
the enzyme activity of the protein.18 Additional testing
in HI individuals from the two families affected by
DFNB89-associated ARNSHI ruled out auditory neuropa-
thy and CMT, thus identifying NSHI as a phenotype asso-
ciated with KARS mutations.
KARS mRNA was detected in isolated hair cells of
chickens and zebrafish, and additional mouse studies
demonstrated strong localization of KARS to otic fibrocytes
and the hair cells and supporting cells of the cochlea. The138 The American Journal of Human Genetics 93, 132–140, July 11, 2presence of this protein within inner-ear structures that are
involved in mechanotransduction provides further evi-
dence of a role for KARS in hearing. Because of the localiza-
tion pattern of KARS within the cochlea, perturbations in
aminoacylationmight affect many of the cellular processes
of the different specialized cells of the cochlea and there-
fore result in hearing impairment. The identification of
rare KARS variants in ARNSHI-affected families defines a
gene that is associated with NSHI.Supplemental Data
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found with this article online at http://www.cell.com/AJHG.Acknowledgments
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